<DOC>
	<DOCNO>NCT00180895</DOCNO>
	<brief_summary>This multicentric phase II study Mabthera ( rituximab ) child adolescent relapse refractory B-cell NHL/L3ALL . The primary objective determine response rate Rituximab single agent relapse refractory Burkitt lymphoma , L3 acute leukemia , large B-cell lymphoma non subclassified aggressive B-cell NHL</brief_summary>
	<brief_title>Rituximab Children Adolescents With Relapsed Refractory B-Cell NHL/L3ALL</brief_title>
	<detailed_description>This multicentric phase II study Mabthera ( rituximab ) child adolescent relapse refractory B-cell NHL/L3ALL . The primary objective determine response rate Rituximab single agent relapse refractory Burkitt lymphoma , L3 acute leukemia , diffuse large B-cell lymphoma non subclassified aggressive B-cell NHL . The secondary objective assess toxicity profile Rituximab child adolescent single agent , follow chemotherapy , study pharmacokinetics Rituximab serum CSF determine overall duration response , time progression survival patient responder antiCD20 initially alone followed chemotherapy . Patients receive Rituximab ( Mabthera ) 375 mg/m2 , week 4 week , administer IV infusion start 50mg/h increase step 50 mg/h every 30mn speed 400 mg/h . Patients combine CNS relapse receive intrathecal injection MTX+HC+Ara-C 48 h injection rituximab First assessment do prior receive 3rd course rituximab . Responding patient ( CR , PR ) patient objective effect ( OE ) receive 3rd 4th injection rituximab start salvage chemotherapy ( COPADM , CYVE/CC course ICE , depend previous chemotherapy regimen receive patient , follow HDCT+ hematopoietic stem cell rescue ) . A second evaluation do 4th course perform .</detailed_description>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically cytologically proven Bcell malignancy , either Burkitt NHL L3 ALL large Bcell lymphoma aggressive Bcell NHL , exception diffuse large Bcell lymphoma arise mediastinum . Immunohistochemistry show CD20 positivity Measurable ( least one bidimensionally measurable lesion ) evaluable ( bone marrow , bone involvement ) disease progression since last evaluation First relapse refractory disease LMB BFM protocol , except isolated CNS relapse Life expectancy &gt; 4 week Performance status ( Karnofsky ) &gt; 30 Adequate hepatic , renal cardiac function Wash 3 week case recent chemotherapy Complete initial workup within 8 day prior treatment Able comply schedule followup management toxicity Written inform consent form adult patient parent legal guardian minor child Active viral infection , especially chronic hepatitis B previous salvage therapy relapse Prior current history severe allergy Primary large Bcell lymphoma mediastinum Isolated CNS relapse</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>B-cell non Hodgkin lymphoma</keyword>
	<keyword>B-cell ALL</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapse</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Children</keyword>
</DOC>